{"gene":"ASNS","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2025,"finding":"Cryo-EM structure reveals that ASX-173 binds a unique hydrophobic pocket formed by AMP, Mg2+, and pyrophosphate in the C-terminal synthetase domain of human ASNS; in vitro kinetic and thermal shift assays show ASX-173 binds the ASNS/Mg2+/ATP complex as an uncompetitive inhibitor, reducing cellular asparagine levels and inducing the integrated stress response.","method":"Cryo-EM structure determination, in vitro kinetic assays, thermal shift assays, cellular asparagine measurement","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure plus orthogonal in vitro kinetic and thermal shift assays in a single study; preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.10.16.682859"],"is_preprint":true},{"year":2023,"finding":"Purified FLAG-tagged ASNS variants R49Q, G289A, and T337I associated with ASNS deficiency show reductions in enzymatic activity of 90%, 36%, and 96% respectively, as measured by AMP production in vitro, establishing that disease-causing ASNS mutations reduce catalytic activity.","method":"In vitro enzymatic assay (AMP detection) of purified FLAG-tagged ASNS variants from stably expressing HEK 293T cells","journal":"Biology methods & protocols","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified proteins and direct enzymatic measurement; multiple variants tested; single lab","pmids":["37965492"],"is_preprint":false},{"year":2006,"finding":"In cybrid cells harboring MELAS and NARP mtDNA mutations, ASNS transcription is upregulated via ATF4 binding to the NSRE-1 (nutrient-sensing response element-1) in the ASNS promoter; ATF4 knockdown by RNAi reduced ASNS transcription, establishing ATF4 as a transcriptional activator of ASNS.","method":"Reporter assay (NSRE-1 element), RNA interference (ATF4 knockdown), DNA microarray, western blot","journal":"Mitochondrion","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus RNAi knockdown with transcription readout; two orthogonal methods; single lab","pmids":["17276738"],"is_preprint":false},{"year":2013,"finding":"During amino acid response (AAR) activation, ATF4 is recruited to the ASNS promoter, accompanied by increases in histone H3K4me3 and H4 acetylation marks and a concurrent loss of total histone H3 near the promoter; removal of AAR stress rapidly reverses H4Ac and ATF4 binding but not H3K4me3, and a second AAR challenge does not alter the kinetics of ASNS induction.","method":"Chromatin immunoprecipitation (ChIP), transcription run-on assays, histone modification analysis in HepG2 cells","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with multiple histone marks and ATF4 binding, functional transcription assays; single lab, two orthogonal methods","pmids":["22978410"],"is_preprint":false},{"year":2018,"finding":"GCN2 kinase is required for ASNS induction in response to L-asparaginase-induced asparagine depletion; pharmacological GCN2 inhibition prevents ASNS upregulation and sensitizes ASNS-low cancer cells (ALL, AML, pancreatic cancer) to asparaginase in vitro and in vivo, placing GCN2 upstream of ASNS in the amino acid response pathway.","method":"GCN2 inhibitor treatment, gene-expression profiling, in vitro cell viability, in vivo mouse xenograft models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with in vitro and in vivo validation; multiple cancer cell lines; single lab","pmids":["30061420"],"is_preprint":false},{"year":2023,"finding":"ATF4 directly binds the ASNS promoter region (ChIP-qPCR) and its overexpression upregulates p-GCN2 and ASNS expression, while ATF4 knockdown reduces ASNS transcription, confirming ATF4 as a direct transcriptional activator of ASNS in colon cancer cells.","method":"ChIP-qPCR, RT-qPCR, western blot, ATF4 knockdown and overexpression in SW480 cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR shows direct promoter binding plus functional gain/loss-of-function; single lab","pmids":["38844625"],"is_preprint":false},{"year":2023,"finding":"TLK2 promotes ASNS expression via two mechanisms: (1) TLK2 directly interacts with ATF4 (a transcription factor for ASNS) and promotes its expression at the mRNA level; (2) mTORC1 directly interacts with ASNS protein and inhibits its ubiquitin-proteasome degradation. TLK2 knockdown suppresses amino acid synthesis by downregulating the mTORC1 pathway and ASNS expression.","method":"IP-MS, co-immunoprecipitation, ubiquitination assay, pathway inhibitor/activator experiments, western blot","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/IP-MS for protein interactions, ubiquitination assay for degradation mechanism; single lab, multiple orthogonal methods","pmids":["37542132"],"is_preprint":false},{"year":2024,"finding":"METTL3-mediated m6A modification of ASNS mRNA promotes its stability; METTL3 inhibition (STM2457) or knockdown reduces m6A modification on ASNS mRNA, decreasing ASNS mRNA stability and protein expression; ASNS overexpression rescues growth defects caused by METTL3 inhibition.","method":"MeRIP-qPCR, mRNA stability assay (actinomycin D), western blot, overexpression rescue, dual-luciferase reporter","journal":"Journal of Cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-qPCR confirms m6A modification of ASNS mRNA, mRNA stability assay, functional rescue; single lab, multiple orthogonal methods","pmids":["39132158"],"is_preprint":false},{"year":2025,"finding":"HDAC5 deacetylates RXRA at K410 and K412, stabilizing RXRA by reducing ubiquitination; deacetylated RXRA acts as a transcriptional repressor of ASNS by binding the -1114/-1104 region of the ASNS promoter, thereby suppressing asparagine synthesis. CCT196969 inhibits HDAC5, leading to increased RXRA acetylation and decreased ASNS transcription.","method":"Co-immunoprecipitation, ChIP assay, luciferase reporter assay, mass spectrometry (deacetylation site mapping), CETSA, SPR, IP/ubiquitination assay","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP defines binding site, Co-IP/MS maps deacetylation site, luciferase confirms promoter regulation; single lab, multiple orthogonal methods","pmids":["40781327"],"is_preprint":false},{"year":2026,"finding":"VHL E3 ubiquitin ligase interacts with ASNS protein and promotes its ubiquitination and degradation; ASNS overexpression activates PI3K-AKT and MAPK signaling pathways by binding to and inhibiting Junction plakoglobin (JUP) expression, promoting RCC cell growth and metastasis.","method":"Immunoprecipitation, ubiquitination modification proteomics, western blotting, TMT proteomics, RNA sequencing, cell phenotype and animal experiments","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitination proteomics establish VHL-ASNS interaction and ubiquitination; functional pathway activation confirmed; single lab","pmids":["41943831"],"is_preprint":false},{"year":2025,"finding":"GPS2 binds ATF4 protein and stabilizes it by blocking the interaction between ATF4 and its E3 ubiquitin ligase BTRC, thereby preventing ubiquitin-proteasome degradation of ATF4 and maintaining elevated ASNS expression, which confers L-asparaginase resistance in ALL cells.","method":"Co-immunoprecipitation (GPS2-ATF4 and ATF4-BTRC interactions), ubiquitination assay, GPS2 knockdown in vitro and xenograft in vivo","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrates protein interactions, ubiquitination assay shows ATF4 stabilization mechanism, in vivo validation; single lab","pmids":["40693356"],"is_preprint":false},{"year":2020,"finding":"ASNS CpG island promoter is allele-specifically methylated in BCP-ALL cells (aberrant imprinting), which silences ASNS gene expression; higher ASNS methylation correlates with lower ASNS protein expression and higher L-asparaginase sensitivity in three BCP-ALL cohorts. This methylation is associated with aberrant methylation of an imprinted gene cluster at 7q21.","method":"Bisulfite sequencing, methylation analysis, allele-specific methylation mapping, protein expression analysis, in vitro asparaginase sensitivity assays, ETV6-RUNX1 knockin mouse model","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple BCP-ALL cohorts plus mouse model; epigenetic mechanism linked to protein expression and drug sensitivity; replicated across cohorts","pmids":["32573712"],"is_preprint":false},{"year":2022,"finding":"In vitro, supraphysiological or physiological concentrations of asparagine suppress de novo asparagine biosynthesis by ASNS regardless of ASNS expression level, as shown by [U-13C5]-L-glutamine isotope tracing; overexpressing ASNS in ASNase-sensitive B cell lymphoma was insufficient to confer resistance to ASNase in vivo.","method":"13C isotope tracing ([U-13C5]-L-glutamine) in vitro and in vivo, ASNS overexpression in mouse B cell lymphoma model","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isotope tracing in vitro and in vivo with genetic overexpression; single lab, two orthogonal approaches","pmids":["35857457"],"is_preprint":false},{"year":2022,"finding":"ASNS expression peaks in effector CD8+ T cells and declines during memory formation; ASNS overexpression promotes an effector phenotype and enhances anti-tumor responses of adoptively transferred CD8+ T cells in a mouse melanoma model, establishing ASNS expression dynamics as a functional modulator of T cell differentiation.","method":"Single-cell RNA sequencing, ASNS overexpression in CD8+ T cells, adoptive transfer in mouse melanoma model, functional differentiation assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — scRNA-seq for expression dynamics corroborated by functional overexpression and in vivo adoptive transfer; single lab","pmids":["36384124"],"is_preprint":false},{"year":2023,"finding":"DOT1L inhibition reduces EZH2/PRC2 pathway activity, which converges on increased ASNS expression; overexpression of ASNS in apical progenitors (APs) phenocopies DOT1L inhibition by increasing neuronal differentiation, placing ASNS downstream of DOT1L/EZH2 epigenetic regulation in cortical neurogenesis.","method":"DOT1L inhibitor treatment, single-cell RNA sequencing, lineage tracing, ASNS overexpression in neural progenitors, clonal analysis","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis established by inhibitor treatment and overexpression rescue with clonal lineage tracing; single lab","pmids":["37382163"],"is_preprint":false},{"year":2025,"finding":"METTL1-mediated m7G modification of ASNS mRNA increases its stability and expression in hepatocellular carcinoma; METTL1 knockdown reduces ASNS mRNA stability and expression, while METTL1 drives HCC progression through ASNS-dependent asparagine metabolism and mTOR pathway activation.","method":"Multi-omics analysis (m7G modification mapping), mRNA stability assay, METTL1 knockdown and overexpression, mTOR pathway analysis","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — abstract describes m7G modification of ASNS mRNA and functional consequences but limited methodological detail; single lab","pmids":["42045536"],"is_preprint":false},{"year":2021,"finding":"In Saccharomyces cerevisiae, ASNS (Asn1) forms cytoophidia (filamentous assemblies) that are shorter than CTP synthase (CTPS) cytoophidia; disruption of ASNS shortens CTPS cytoophidial length, but CTPS deletion does not affect ASNS cytoophidium formation or ASNS protein level. ASNS overexpression in diauxic phase induces multi-dot structures, suggesting protein level drives cytoophidia formation.","method":"Genetic deletion (ASNS and CTPS knockouts in yeast), fluorescence microscopy of cytoophidia, protein level analysis","journal":"G3 (Bethesda, Md.)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast ortholog study with genetic deletion and microscopy; directional epistasis established; single lab, yeast model","pmids":["33561249"],"is_preprint":false},{"year":2025,"finding":"ASNS protein binds USP13 and increases USP13 expression; in ARPE-19 retinal epithelial cells, ASNS overexpression reduces ROS production and SA-β-gal staining (senescence marker), and enhances glycolysis and oxidative phosphorylation, suggesting ASNS acts through an ASNS/USP13 axis to protect against oxidative stress.","method":"Co-immunoprecipitation (ASNS-USP13), ASNS overexpression, ROS measurement, SA-β-gal staining, ECAR/OCR measurement in ARPE-19 cells","journal":"BioFactors (Oxford, England)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP for interaction, single lab, limited mechanistic detail in abstract","pmids":["41293996"],"is_preprint":false},{"year":2025,"finding":"PGG (1,2,3,4,6-O-Pentagalloylglucose) inhibits purified recombinant human ASNS with KD = 8.8 μM and IC50 = 7.1 μM in enzymatic assay, thereby increasing cellular L-aspartate levels and activating the LKB1/AMPK metabolic axis, reducing hepatic lipid accumulation in mice on high-fat/high-cholesterol diet.","method":"FEP-based virtual screening, binding affinity assay (KD), in vitro enzymatic inhibition assay (IC50), cellular aspartate measurement, LKB1/AMPK pathway analysis, in vivo mouse MASLD model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay with purified recombinant ASNS, binding affinity measurement, in vivo validation; single lab","pmids":["40409103"],"is_preprint":false},{"year":2025,"finding":"ASX-173 is a cell-permeable small molecule that inhibits ASNS at nanomolar concentrations; combination of ASX-173 with L-asparaginase disrupts nucleotide synthesis and induces cell cycle arrest and apoptosis; in a mouse AML xenograft model, the combination significantly delayed tumor growth.","method":"Biochemical ASNS inhibition assay, cell viability assays, cell cycle/apoptosis analysis, nucleotide synthesis measurement, mouse xenograft model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical and cellular assays with in vivo validation; multiple orthogonal methods; preprint","pmids":["bio_10.1101_2025.07.03.662851"],"is_preprint":true}],"current_model":"Human ASNS catalyzes the ATP- and glutamine-dependent conversion of aspartate to asparagine (generating glutamate, AMP, and pyrophosphate); its transcription is directly activated by ATF4 binding to the NSRE-1 promoter element during amino acid deprivation, placing it downstream of the GCN2 kinase arm of the integrated stress response. ASNS protein stability is regulated by ubiquitin-proteasome degradation (controlled by mTORC1, VHL, and the GPS2/BTRC/ATF4 axis), while its mRNA stability is enhanced by METTL3-mediated m6A and METTL1-mediated m7G modifications. Disease-causing missense mutations reduce catalytic activity, and a cryo-EM structure of an uncompetitive small-molecule inhibitor (ASX-173) bound to the ASNS/AMP/Mg2+/pyrophosphate complex in the C-terminal synthetase domain has been determined, providing a structural basis for therapeutic targeting."},"narrative":{"mechanistic_narrative":"ASNS is the metabolic enzyme that catalyzes ATP-dependent de novo asparagine biosynthesis, with catalysis residing in a C-terminal synthetase domain where AMP, Mg2+, and pyrophosphate define the active-site architecture [PMID:bio_10.1101_2025.10.16.682859]; disease-associated missense substitutions (R49Q, G289A, T337I) that diminish AMP-producing catalytic activity establish the enzyme's clinical importance [PMID:37965492]. Its expression is governed primarily at the transcriptional level by the amino acid response: GCN2 kinase signaling drives recruitment of ATF4 to the ASNS promoter at the NSRE-1 element, where ATF4 binding is accompanied by activating histone marks (H3K4me3, H4 acetylation), to induce transcription during amino acid or asparagine deprivation [PMID:17276738, PMID:22978410, PMID:30061420, PMID:38844625]. ASNS abundance is further set by layered post-transcriptional and post-translational control: mRNA stability is enhanced by METTL3-mediated m6A modification [PMID:39132158], while protein turnover is shaped by ubiquitin-proteasome degradation involving mTORC1 (which protects ASNS from degradation) [PMID:37542132] and the VHL E3 ligase (which ubiquitinates ASNS) [PMID:41943831]; the upstream ATF4 driver is itself stabilized by GPS2 blocking its BTRC-mediated degradation [PMID:40693356]. Through this regulatory network ASNS modulates cellular asparagine supply with consequences for L-asparaginase sensitivity in leukemia [PMID:32573712], CD8+ T cell effector differentiation [PMID:36384124], and cortical neurogenesis [PMID:37382163], and it is being pharmacologically targeted: the uncompetitive inhibitor ASX-173 binds the synthetase-domain ASNS/AMP/Mg2+/pyrophosphate complex and, combined with asparaginase, induces the integrated stress response and antitumor effects [PMID:bio_10.1101_2025.10.16.682859, PMID:bio_10.1101_2025.07.03.662851].","teleology":[{"year":2006,"claim":"Established the transcriptional logic of ASNS induction by identifying ATF4 as the activator acting through the NSRE-1 promoter element under metabolic stress.","evidence":"Reporter assay of NSRE-1, ATF4 RNAi knockdown, and microarray in MELAS/NARP cybrid cells","pmids":["17276738"],"confidence":"Medium","gaps":["Did not resolve the chromatin events accompanying ATF4 binding","Upstream kinase signaling not defined in this study"]},{"year":2013,"claim":"Defined the chromatin dynamics of ASNS activation, showing ATF4 recruitment coincides with specific histone modifications and reversible promoter remodeling during the amino acid response.","evidence":"ChIP for ATF4 and histone marks plus transcription run-on assays in HepG2 cells","pmids":["22978410"],"confidence":"Medium","gaps":["Functional necessity of each histone mark for induction not dissected","Did not establish the signaling kinase upstream of ATF4"]},{"year":2018,"claim":"Placed GCN2 kinase upstream of ASNS in the amino acid response, linking sensing of asparagine depletion to ASNS induction and to asparaginase sensitivity in cancer.","evidence":"Pharmacological GCN2 inhibition with expression profiling, in vitro viability, and mouse xenografts in ALL/AML/pancreatic models","pmids":["30061420"],"confidence":"Medium","gaps":["Relied on pharmacological inhibition rather than genetic ablation","Direct GCN2-ATF4-ASNS molecular chain not reconstituted"]},{"year":2020,"claim":"Connected epigenetic silencing of ASNS to drug response by showing allele-specific promoter methylation suppresses ASNS and predicts asparaginase sensitivity in leukemia.","evidence":"Bisulfite/allele-specific methylation mapping across three BCP-ALL cohorts and an ETV6-RUNX1 knockin mouse model","pmids":["32573712"],"confidence":"Medium","gaps":["Mechanism linking 7q21 imprinting cluster to ASNS not fully defined","Causal contribution of methylation versus correlation not isolated"]},{"year":2022,"claim":"Tested the prevailing assumption that ASNS level dictates asparaginase resistance, finding feedback suppression of biosynthesis by asparagine and that ASNS overexpression alone is insufficient for resistance in vivo.","evidence":"13C-glutamine isotope tracing and ASNS overexpression in a mouse B cell lymphoma model","pmids":["35857457"],"confidence":"Medium","gaps":["Microenvironmental asparagine sources not fully accounted for","Mechanism of biosynthetic feedback suppression not molecularly defined"]},{"year":2022,"claim":"Extended ASNS function beyond housekeeping metabolism by identifying its expression dynamics as a regulator of CD8+ T cell effector versus memory differentiation.","evidence":"Single-cell RNA-seq, ASNS overexpression, and adoptive transfer in a mouse melanoma model","pmids":["36384124"],"confidence":"Medium","gaps":["Metabolic versus signaling basis of the differentiation effect unresolved","Whether catalytic activity is required not tested"]},{"year":2023,"claim":"Quantified the catalytic consequences of ASNS deficiency mutations, directly linking specific missense variants to graded loss of enzymatic activity.","evidence":"In vitro AMP-production assays of purified FLAG-tagged R49Q, G289A, T337I variants from HEK293T cells","pmids":["37965492"],"confidence":"High","gaps":["Structural basis of activity loss for each variant not resolved","Effects on protein stability or folding not separated from catalysis"]},{"year":2023,"claim":"Identified dual upstream control of ASNS by TLK2, acting through ATF4 transcription and through mTORC1-mediated protection of ASNS protein from degradation.","evidence":"IP-MS, co-IP, and ubiquitination assays with pathway modulators","pmids":["37542132"],"confidence":"Medium","gaps":["E3 ligase opposing mTORC1 protection not identified here","Direct versus indirect nature of mTORC1-ASNS interaction not fully resolved"]},{"year":2023,"claim":"Confirmed direct ATF4 binding to the ASNS promoter in an independent cancer context, reinforcing the GCN2-ATF4-ASNS transcriptional axis.","evidence":"ChIP-qPCR with ATF4 gain- and loss-of-function in SW480 colon cancer cells","pmids":["38844625"],"confidence":"Medium","gaps":["Did not add new mechanistic layers beyond confirming direct binding"]},{"year":2023,"claim":"Positioned ASNS downstream of DOT1L/EZH2 epigenetic regulation in cortical neurogenesis, where elevated ASNS promotes neuronal differentiation.","evidence":"DOT1L inhibition, scRNA-seq, lineage tracing, and ASNS overexpression rescue in neural progenitors","pmids":["37382163"],"confidence":"Medium","gaps":["Direct transcriptional link from EZH2/PRC2 to ASNS not defined","Whether the effect requires ASNS catalysis untested"]},{"year":2024,"claim":"Revealed m6A-based post-transcriptional control of ASNS, with METTL3 stabilizing ASNS mRNA to maintain protein levels and growth.","evidence":"MeRIP-qPCR, actinomycin D stability assay, luciferase reporter, and overexpression rescue","pmids":["39132158"],"confidence":"Medium","gaps":["m6A reader mediating stability not identified","Specific m6A sites on ASNS mRNA not mapped"]},{"year":2025,"claim":"Defined the structural basis for therapeutic targeting of ASNS by solving an inhibitor-bound cryo-EM structure and showing uncompetitive inhibition that lowers asparagine and triggers the integrated stress response.","evidence":"Cryo-EM of ASX-173/ASNS/AMP/Mg2+/pyrophosphate plus in vitro kinetics and thermal shift assays (preprint)","pmids":["bio_10.1101_2025.10.16.682859"],"confidence":"High","gaps":["Preprint not yet peer-reviewed","Selectivity against related synthetases not detailed"]},{"year":2025,"claim":"Identified additional ubiquitin-proteasome and transcriptional repression nodes (VHL ubiquitination of ASNS; GPS2 stabilization of ATF4; HDAC5/RXRA repression) that set ASNS abundance and downstream signaling.","evidence":"Co-IP, ubiquitination/TMT proteomics, ChIP, and luciferase assays with in vivo validation across RCC, ALL, and cancer models","pmids":["41943831","40693356","40781327"],"confidence":"Medium","gaps":["Hierarchy among these regulators in a single cell type not established","Reciprocal validation of some interactions limited to single labs"]},{"year":2025,"claim":"Advanced ASNS as a druggable target with two distinct small-molecule inhibitors (ASX-173, PGG) showing antitumor and metabolic effects through enzymatic inhibition.","evidence":"Biochemical inhibition of purified ASNS, cellular and metabolic readouts, and mouse AML xenograft / MASLD models","pmids":["bio_10.1101_2025.07.03.662851","40409103"],"confidence":"Medium","gaps":["Long-term resistance mechanisms not addressed","ASX-173 evidence partly from preprint"]},{"year":null,"claim":"How the multiple parallel regulatory layers (GCN2/ATF4 transcription, m6A/m7G mRNA modification, mTORC1/VHL/GPS2-BTRC turnover, and epigenetic silencing) are integrated to set ASNS activity in a given tissue or tumor remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model relating transcriptional, post-transcriptional, and degradative control","Tissue-specific dominance of each regulatory node unknown","Relationship between ASNS catalytic output and its non-metabolic signaling roles undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,1]}],"localization":[],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,12]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[2,3,4]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,5]}],"complexes":[],"partners":["ATF4","MTORC1","VHL","USP13","TLK2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08243","full_name":"Asparagine synthetase [glutamine-hydrolyzing]","aliases":["Cell cycle control protein TS11","Glutamine-dependent asparagine synthetase"],"length_aa":561,"mass_kda":64.4,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P08243/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ASNS","classification":"Not Classified","n_dependent_lines":214,"n_total_lines":1208,"dependency_fraction":0.1771523178807947},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ASNS","total_profiled":1310},"omim":[{"mim_id":"615886","title":"SCAFFOLDING CK1-ANCHORING PROTEIN G; SACK1G","url":"https://www.omim.org/entry/615886"},{"mim_id":"615574","title":"ASPARAGINE SYNTHETASE DEFICIENCY; ASNSD","url":"https://www.omim.org/entry/615574"},{"mim_id":"604735","title":"UBIQUITIN-SPECIFIC PROTEASE 16; USP16","url":"https://www.omim.org/entry/604735"},{"mim_id":"604064","title":"ACTIVATING TRANSCRIPTION FACTOR 4; ATF4","url":"https://www.omim.org/entry/604064"},{"mim_id":"183600","title":"SPLIT-HAND/FOOT MALFORMATION 1; SHFM1","url":"https://www.omim.org/entry/183600"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"pancreas","ntpm":114.4}],"url":"https://www.proteinatlas.org/search/ASNS"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P08243","domains":[{"cath_id":"3.60.20.10","chopping":"4-204","consensus_level":"high","plddt":95.187,"start":4,"end":204},{"cath_id":"3.40.50.620","chopping":"254-552","consensus_level":"high","plddt":95.716,"start":254,"end":552}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08243","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08243-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08243-F1-predicted_aligned_error_v6.png","plddt_mean":94.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ASNS","jax_strain_url":"https://www.jax.org/strain/search?query=ASNS"},"sequence":{"accession":"P08243","fasta_url":"https://rest.uniprot.org/uniprotkb/P08243.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08243/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08243"}},"corpus_meta":[{"pmid":"30061420","id":"PMC_30061420","title":"Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30061420","citation_count":149,"is_preprint":false},{"pmid":"24659632","id":"PMC_24659632","title":"The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24659632","citation_count":148,"is_preprint":false},{"pmid":"27251594","id":"PMC_27251594","title":"Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.","date":"2016","source":"Scandinavian journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27251594","citation_count":40,"is_preprint":false},{"pmid":"36384124","id":"PMC_36384124","title":"CD8+ T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36384124","citation_count":36,"is_preprint":false},{"pmid":"27422383","id":"PMC_27422383","title":"Hyperekplexia, microcephaly and simplified gyral pattern caused by novel ASNS mutations, case report.","date":"2016","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27422383","citation_count":31,"is_preprint":false},{"pmid":"17276738","id":"PMC_17276738","title":"CHOP (C/EBP homologous protein) and ASNS (asparagine synthetase) induction in cybrid cells harboring MELAS and NARP mitochondrial DNA mutations.","date":"2006","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/17276738","citation_count":29,"is_preprint":false},{"pmid":"6836455","id":"PMC_6836455","title":"Isolation and characterization of interspecific heat-resistant hybrids between a temperature-sensitive chinese hamster cell asparaginyl-tRNA synthetase mutant and normal human leukocytes: assignment of human asnS gene to chromosome 18.","date":"1983","source":"Somatic cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6836455","citation_count":27,"is_preprint":false},{"pmid":"35857457","id":"PMC_35857457","title":"Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35857457","citation_count":26,"is_preprint":false},{"pmid":"7904551","id":"PMC_7904551","title":"Refined localization of the asparagine synthetase gene (ASNS) to chromosome 7, region q21.3, and characterization of the somatic cell hybrid line 4AF/106/KO15.","date":"1994","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7904551","citation_count":24,"is_preprint":false},{"pmid":"31123592","id":"PMC_31123592","title":"Clinical outcomes of two patients with a novel pathogenic variant in ASNS: response to asparagine supplementation and review of the literature.","date":"2019","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/31123592","citation_count":24,"is_preprint":false},{"pmid":"32573712","id":"PMC_32573712","title":"Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32573712","citation_count":22,"is_preprint":false},{"pmid":"27469131","id":"PMC_27469131","title":"Diaphragmatic Eventration in Sisters with Asparagine Synthetase Deficiency: A Novel Homozygous ASNS Mutation and Expanded Phenotype.","date":"2016","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/27469131","citation_count":22,"is_preprint":false},{"pmid":"33615182","id":"PMC_33615182","title":"Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms.","date":"2021","source":"ACS pharmacology & translational science","url":"https://pubmed.ncbi.nlm.nih.gov/33615182","citation_count":22,"is_preprint":false},{"pmid":"30057589","id":"PMC_30057589","title":"Novel Mutations in the Asparagine Synthetase Gene (ASNS) Associated With Microcephaly.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30057589","citation_count":19,"is_preprint":false},{"pmid":"24268318","id":"PMC_24268318","title":"Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.","date":"2013","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/24268318","citation_count":19,"is_preprint":false},{"pmid":"37382163","id":"PMC_37382163","title":"DOT1L activity affects neural stem cell division mode and reduces differentiation and ASNS expression.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37382163","citation_count":16,"is_preprint":false},{"pmid":"30978478","id":"PMC_30978478","title":"Molecular diagnosis of asparagine synthetase (ASNS) deficiency in two Indian families and literature review of 29 ASNS deficient cases.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30978478","citation_count":15,"is_preprint":false},{"pmid":"23382816","id":"PMC_23382816","title":"Cell cycle-dependent recruitment of polycomb proteins to the ASNS promoter counteracts C/ebp-mediated transcriptional activation in Bombyx mori.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23382816","citation_count":13,"is_preprint":false},{"pmid":"37542132","id":"PMC_37542132","title":"Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37542132","citation_count":12,"is_preprint":false},{"pmid":"35469797","id":"PMC_35469797","title":"An intractable epilepsy phenotype of ASNS novel mutation in two patients with asparagine synthetase deficiency.","date":"2022","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35469797","citation_count":12,"is_preprint":false},{"pmid":"39132158","id":"PMC_39132158","title":"METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation.","date":"2024","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39132158","citation_count":11,"is_preprint":false},{"pmid":"32906196","id":"PMC_32906196","title":"Rapid exome sequencing and adjunct RNA studies confirm the pathogenicity of a novel homozygous ASNS splicing variant in a critically ill neonate.","date":"2020","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/32906196","citation_count":11,"is_preprint":false},{"pmid":"38844625","id":"PMC_38844625","title":"ATF4 inhibits tumor development and mediates p-GCN2/ASNS upregulation in colon cancer.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38844625","citation_count":10,"is_preprint":false},{"pmid":"33561249","id":"PMC_33561249","title":"ASNS disruption shortens CTPS cytoophidia in Saccharomyces cerevisiae.","date":"2021","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33561249","citation_count":10,"is_preprint":false},{"pmid":"34540668","id":"PMC_34540668","title":"Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34540668","citation_count":10,"is_preprint":false},{"pmid":"32255274","id":"PMC_32255274","title":"A novel compound heterozygous missense mutation in ASNS broadens the spectrum of asparagine synthetase deficiency.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32255274","citation_count":9,"is_preprint":false},{"pmid":"38370444","id":"PMC_38370444","title":"Modifications of the GH Axis Reveal Unique Sexually Dimorphic Liver Signatures for Lcn13, Asns, Hamp2, Hao2, and Pgc1a.","date":"2024","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/38370444","citation_count":9,"is_preprint":false},{"pmid":"22978410","id":"PMC_22978410","title":"Dynamic changes in genomic histone association and modification during activation of the ASNS and ATF3 genes by amino acid limitation.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/22978410","citation_count":9,"is_preprint":false},{"pmid":"30844524","id":"PMC_30844524","title":"Cyst-Peritoneal Shunt for the Treatment of a Progressive Intracerebral Cyst Associated with ASNS Mutation: Case Report and Literature Review.","date":"2019","source":"World neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/30844524","citation_count":7,"is_preprint":false},{"pmid":"40693356","id":"PMC_40693356","title":"GPS2 confers l-asparaginase resistance in acute lymphoblastic leukemia cells through ATF4/ASNS axis.","date":"2025","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/40693356","citation_count":4,"is_preprint":false},{"pmid":"37900678","id":"PMC_37900678","title":"Case report: A compound heterozygous mutations in ASNS broadens the spectrum of asparagine synthetase deficiency in the prenatal diagnosis.","date":"2023","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/37900678","citation_count":4,"is_preprint":false},{"pmid":"40781327","id":"PMC_40781327","title":"CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/40781327","citation_count":3,"is_preprint":false},{"pmid":"37839090","id":"PMC_37839090","title":"Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL.","date":"2023","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/37839090","citation_count":3,"is_preprint":false},{"pmid":"37965492","id":"PMC_37965492","title":"A method for measurement of human asparagine synthetase (ASNS) activity and application to ASNS protein variants associated with ASNS deficiency.","date":"2023","source":"Biology methods & protocols","url":"https://pubmed.ncbi.nlm.nih.gov/37965492","citation_count":2,"is_preprint":false},{"pmid":"38546112","id":"PMC_38546112","title":"A novel variant in ASNS gene responsible for syndromic intellectual disability and microcephaly: Case report and literature review.","date":"2024","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38546112","citation_count":2,"is_preprint":false},{"pmid":"40409103","id":"PMC_40409103","title":"Identification of 1,2,3,4,6-O-Pentagalloylglucose as a novel ASNS inhibitor for MASLD amelioration in mice by increasing l-aspartate levels alongside LKB1/AMPK metabolic axis activation.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40409103","citation_count":2,"is_preprint":false},{"pmid":"40406431","id":"PMC_40406431","title":"Targeting the NCAPD3 gene activates EGFR and ASNS as two pivotal contributors to gastric cancer progression.","date":"2024","source":"Gastroenterology and hepatology from bed to bench","url":"https://pubmed.ncbi.nlm.nih.gov/40406431","citation_count":1,"is_preprint":false},{"pmid":"41293996","id":"PMC_41293996","title":"ASNS Regulates H2O2-Induced Senescence, Oxidative Stress, and Glucose Metabolism in ARPE-19 Cells by Modulating USP13 Expression.","date":"2025","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/41293996","citation_count":1,"is_preprint":false},{"pmid":"21208570","id":"PMC_21208570","title":"[Preparation of anti-ASNS monoclonal antibody and detection of ASNS expression in tumor].","date":"2011","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21208570","citation_count":0,"is_preprint":false},{"pmid":"41463097","id":"PMC_41463097","title":"Asparagine synthetase (ASNS) Drives Tumorigenicity in Small Cell Lung Cancer.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/41463097","citation_count":0,"is_preprint":false},{"pmid":"41719286","id":"PMC_41719286","title":"Molecular interplay of ASNS and the PI3K-AKT-mTOR pathway in CMV and HIV co-infections: Therapeutic implications.","date":"2026","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/41719286","citation_count":0,"is_preprint":false},{"pmid":"32481472","id":"PMC_32481472","title":"Congenital microcephaly with early onset epileptic encephalopathy caused by ASNS gene mutation: A case report.","date":"2020","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32481472","citation_count":0,"is_preprint":false},{"pmid":"41943831","id":"PMC_41943831","title":"Suppression of ASNS expression by VHL-mediated ubiquitination hinders the progression of renal cell carcinoma through enhancing JUP expression and inhibiting PI3K-AKT and MAPK pathways.","date":"2026","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41943831","citation_count":0,"is_preprint":false},{"pmid":"39445026","id":"PMC_39445026","title":"Multi-omics analyses were combined to construct ubiquitination-related features in colon adenocarcinoma and identify ASNS as a novel biomarker.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39445026","citation_count":0,"is_preprint":false},{"pmid":"42045536","id":"PMC_42045536","title":"METTL1-mediated m7G modification of ASNS mRNA regulates asparagine metabolism reprogramming to promote hepatocellular carcinoma progression.","date":"2026","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/42045536","citation_count":0,"is_preprint":false},{"pmid":"38567172","id":"PMC_38567172","title":"Revisiting Exome Data Identified Missed Splice Site Variant of the Asparagine Synthetase ( ASNS ) Gene.","date":"2022","source":"Journal of pediatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38567172","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.16.682859","title":"Cryo-EM reveals how ASX-173 inhibits human asparagine synthetase to activate the integrated stress response","date":"2025-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.16.682859","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.10.674685","title":"Splicing neoepitope prediction is sensitive to methodological differences","date":"2025-09-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.10.674685","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.03.662851","title":"The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity","date":"2025-07-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.03.662851","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.13.681863","title":"tRNA Modification Landscapes in Streptococci: Shared Losses and Clade-Specific Adaptations","date":"2025-10-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.13.681863","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.03.24319826","title":"Cost-effective and Flexible Preimplantation Genetic Testing (PGT) Using Adaptive Sampling-based Targeted Nanopore Sequencing (ASTN-seq)","date":"2025-01-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.03.24319826","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26452,"output_tokens":5170,"usd":0.078453,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13553,"output_tokens":4291,"usd":0.08752,"stage2_stop_reason":"end_turn"},"total_usd":0.165973,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM structure reveals that ASX-173 binds a unique hydrophobic pocket formed by AMP, Mg2+, and pyrophosphate in the C-terminal synthetase domain of human ASNS; in vitro kinetic and thermal shift assays show ASX-173 binds the ASNS/Mg2+/ATP complex as an uncompetitive inhibitor, reducing cellular asparagine levels and inducing the integrated stress response.\",\n      \"method\": \"Cryo-EM structure determination, in vitro kinetic assays, thermal shift assays, cellular asparagine measurement\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure plus orthogonal in vitro kinetic and thermal shift assays in a single study; preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.10.16.682859\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Purified FLAG-tagged ASNS variants R49Q, G289A, and T337I associated with ASNS deficiency show reductions in enzymatic activity of 90%, 36%, and 96% respectively, as measured by AMP production in vitro, establishing that disease-causing ASNS mutations reduce catalytic activity.\",\n      \"method\": \"In vitro enzymatic assay (AMP detection) of purified FLAG-tagged ASNS variants from stably expressing HEK 293T cells\",\n      \"journal\": \"Biology methods & protocols\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified proteins and direct enzymatic measurement; multiple variants tested; single lab\",\n      \"pmids\": [\"37965492\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In cybrid cells harboring MELAS and NARP mtDNA mutations, ASNS transcription is upregulated via ATF4 binding to the NSRE-1 (nutrient-sensing response element-1) in the ASNS promoter; ATF4 knockdown by RNAi reduced ASNS transcription, establishing ATF4 as a transcriptional activator of ASNS.\",\n      \"method\": \"Reporter assay (NSRE-1 element), RNA interference (ATF4 knockdown), DNA microarray, western blot\",\n      \"journal\": \"Mitochondrion\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus RNAi knockdown with transcription readout; two orthogonal methods; single lab\",\n      \"pmids\": [\"17276738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"During amino acid response (AAR) activation, ATF4 is recruited to the ASNS promoter, accompanied by increases in histone H3K4me3 and H4 acetylation marks and a concurrent loss of total histone H3 near the promoter; removal of AAR stress rapidly reverses H4Ac and ATF4 binding but not H3K4me3, and a second AAR challenge does not alter the kinetics of ASNS induction.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), transcription run-on assays, histone modification analysis in HepG2 cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with multiple histone marks and ATF4 binding, functional transcription assays; single lab, two orthogonal methods\",\n      \"pmids\": [\"22978410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GCN2 kinase is required for ASNS induction in response to L-asparaginase-induced asparagine depletion; pharmacological GCN2 inhibition prevents ASNS upregulation and sensitizes ASNS-low cancer cells (ALL, AML, pancreatic cancer) to asparaginase in vitro and in vivo, placing GCN2 upstream of ASNS in the amino acid response pathway.\",\n      \"method\": \"GCN2 inhibitor treatment, gene-expression profiling, in vitro cell viability, in vivo mouse xenograft models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with in vitro and in vivo validation; multiple cancer cell lines; single lab\",\n      \"pmids\": [\"30061420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ATF4 directly binds the ASNS promoter region (ChIP-qPCR) and its overexpression upregulates p-GCN2 and ASNS expression, while ATF4 knockdown reduces ASNS transcription, confirming ATF4 as a direct transcriptional activator of ASNS in colon cancer cells.\",\n      \"method\": \"ChIP-qPCR, RT-qPCR, western blot, ATF4 knockdown and overexpression in SW480 cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR shows direct promoter binding plus functional gain/loss-of-function; single lab\",\n      \"pmids\": [\"38844625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TLK2 promotes ASNS expression via two mechanisms: (1) TLK2 directly interacts with ATF4 (a transcription factor for ASNS) and promotes its expression at the mRNA level; (2) mTORC1 directly interacts with ASNS protein and inhibits its ubiquitin-proteasome degradation. TLK2 knockdown suppresses amino acid synthesis by downregulating the mTORC1 pathway and ASNS expression.\",\n      \"method\": \"IP-MS, co-immunoprecipitation, ubiquitination assay, pathway inhibitor/activator experiments, western blot\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/IP-MS for protein interactions, ubiquitination assay for degradation mechanism; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37542132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL3-mediated m6A modification of ASNS mRNA promotes its stability; METTL3 inhibition (STM2457) or knockdown reduces m6A modification on ASNS mRNA, decreasing ASNS mRNA stability and protein expression; ASNS overexpression rescues growth defects caused by METTL3 inhibition.\",\n      \"method\": \"MeRIP-qPCR, mRNA stability assay (actinomycin D), western blot, overexpression rescue, dual-luciferase reporter\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-qPCR confirms m6A modification of ASNS mRNA, mRNA stability assay, functional rescue; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39132158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HDAC5 deacetylates RXRA at K410 and K412, stabilizing RXRA by reducing ubiquitination; deacetylated RXRA acts as a transcriptional repressor of ASNS by binding the -1114/-1104 region of the ASNS promoter, thereby suppressing asparagine synthesis. CCT196969 inhibits HDAC5, leading to increased RXRA acetylation and decreased ASNS transcription.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, luciferase reporter assay, mass spectrometry (deacetylation site mapping), CETSA, SPR, IP/ubiquitination assay\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP defines binding site, Co-IP/MS maps deacetylation site, luciferase confirms promoter regulation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"40781327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"VHL E3 ubiquitin ligase interacts with ASNS protein and promotes its ubiquitination and degradation; ASNS overexpression activates PI3K-AKT and MAPK signaling pathways by binding to and inhibiting Junction plakoglobin (JUP) expression, promoting RCC cell growth and metastasis.\",\n      \"method\": \"Immunoprecipitation, ubiquitination modification proteomics, western blotting, TMT proteomics, RNA sequencing, cell phenotype and animal experiments\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitination proteomics establish VHL-ASNS interaction and ubiquitination; functional pathway activation confirmed; single lab\",\n      \"pmids\": [\"41943831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GPS2 binds ATF4 protein and stabilizes it by blocking the interaction between ATF4 and its E3 ubiquitin ligase BTRC, thereby preventing ubiquitin-proteasome degradation of ATF4 and maintaining elevated ASNS expression, which confers L-asparaginase resistance in ALL cells.\",\n      \"method\": \"Co-immunoprecipitation (GPS2-ATF4 and ATF4-BTRC interactions), ubiquitination assay, GPS2 knockdown in vitro and xenograft in vivo\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrates protein interactions, ubiquitination assay shows ATF4 stabilization mechanism, in vivo validation; single lab\",\n      \"pmids\": [\"40693356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASNS CpG island promoter is allele-specifically methylated in BCP-ALL cells (aberrant imprinting), which silences ASNS gene expression; higher ASNS methylation correlates with lower ASNS protein expression and higher L-asparaginase sensitivity in three BCP-ALL cohorts. This methylation is associated with aberrant methylation of an imprinted gene cluster at 7q21.\",\n      \"method\": \"Bisulfite sequencing, methylation analysis, allele-specific methylation mapping, protein expression analysis, in vitro asparaginase sensitivity assays, ETV6-RUNX1 knockin mouse model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple BCP-ALL cohorts plus mouse model; epigenetic mechanism linked to protein expression and drug sensitivity; replicated across cohorts\",\n      \"pmids\": [\"32573712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In vitro, supraphysiological or physiological concentrations of asparagine suppress de novo asparagine biosynthesis by ASNS regardless of ASNS expression level, as shown by [U-13C5]-L-glutamine isotope tracing; overexpressing ASNS in ASNase-sensitive B cell lymphoma was insufficient to confer resistance to ASNase in vivo.\",\n      \"method\": \"13C isotope tracing ([U-13C5]-L-glutamine) in vitro and in vivo, ASNS overexpression in mouse B cell lymphoma model\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isotope tracing in vitro and in vivo with genetic overexpression; single lab, two orthogonal approaches\",\n      \"pmids\": [\"35857457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASNS expression peaks in effector CD8+ T cells and declines during memory formation; ASNS overexpression promotes an effector phenotype and enhances anti-tumor responses of adoptively transferred CD8+ T cells in a mouse melanoma model, establishing ASNS expression dynamics as a functional modulator of T cell differentiation.\",\n      \"method\": \"Single-cell RNA sequencing, ASNS overexpression in CD8+ T cells, adoptive transfer in mouse melanoma model, functional differentiation assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — scRNA-seq for expression dynamics corroborated by functional overexpression and in vivo adoptive transfer; single lab\",\n      \"pmids\": [\"36384124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DOT1L inhibition reduces EZH2/PRC2 pathway activity, which converges on increased ASNS expression; overexpression of ASNS in apical progenitors (APs) phenocopies DOT1L inhibition by increasing neuronal differentiation, placing ASNS downstream of DOT1L/EZH2 epigenetic regulation in cortical neurogenesis.\",\n      \"method\": \"DOT1L inhibitor treatment, single-cell RNA sequencing, lineage tracing, ASNS overexpression in neural progenitors, clonal analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis established by inhibitor treatment and overexpression rescue with clonal lineage tracing; single lab\",\n      \"pmids\": [\"37382163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL1-mediated m7G modification of ASNS mRNA increases its stability and expression in hepatocellular carcinoma; METTL1 knockdown reduces ASNS mRNA stability and expression, while METTL1 drives HCC progression through ASNS-dependent asparagine metabolism and mTOR pathway activation.\",\n      \"method\": \"Multi-omics analysis (m7G modification mapping), mRNA stability assay, METTL1 knockdown and overexpression, mTOR pathway analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — abstract describes m7G modification of ASNS mRNA and functional consequences but limited methodological detail; single lab\",\n      \"pmids\": [\"42045536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In Saccharomyces cerevisiae, ASNS (Asn1) forms cytoophidia (filamentous assemblies) that are shorter than CTP synthase (CTPS) cytoophidia; disruption of ASNS shortens CTPS cytoophidial length, but CTPS deletion does not affect ASNS cytoophidium formation or ASNS protein level. ASNS overexpression in diauxic phase induces multi-dot structures, suggesting protein level drives cytoophidia formation.\",\n      \"method\": \"Genetic deletion (ASNS and CTPS knockouts in yeast), fluorescence microscopy of cytoophidia, protein level analysis\",\n      \"journal\": \"G3 (Bethesda, Md.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast ortholog study with genetic deletion and microscopy; directional epistasis established; single lab, yeast model\",\n      \"pmids\": [\"33561249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ASNS protein binds USP13 and increases USP13 expression; in ARPE-19 retinal epithelial cells, ASNS overexpression reduces ROS production and SA-β-gal staining (senescence marker), and enhances glycolysis and oxidative phosphorylation, suggesting ASNS acts through an ASNS/USP13 axis to protect against oxidative stress.\",\n      \"method\": \"Co-immunoprecipitation (ASNS-USP13), ASNS overexpression, ROS measurement, SA-β-gal staining, ECAR/OCR measurement in ARPE-19 cells\",\n      \"journal\": \"BioFactors (Oxford, England)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP for interaction, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"41293996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PGG (1,2,3,4,6-O-Pentagalloylglucose) inhibits purified recombinant human ASNS with KD = 8.8 μM and IC50 = 7.1 μM in enzymatic assay, thereby increasing cellular L-aspartate levels and activating the LKB1/AMPK metabolic axis, reducing hepatic lipid accumulation in mice on high-fat/high-cholesterol diet.\",\n      \"method\": \"FEP-based virtual screening, binding affinity assay (KD), in vitro enzymatic inhibition assay (IC50), cellular aspartate measurement, LKB1/AMPK pathway analysis, in vivo mouse MASLD model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay with purified recombinant ASNS, binding affinity measurement, in vivo validation; single lab\",\n      \"pmids\": [\"40409103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ASX-173 is a cell-permeable small molecule that inhibits ASNS at nanomolar concentrations; combination of ASX-173 with L-asparaginase disrupts nucleotide synthesis and induces cell cycle arrest and apoptosis; in a mouse AML xenograft model, the combination significantly delayed tumor growth.\",\n      \"method\": \"Biochemical ASNS inhibition assay, cell viability assays, cell cycle/apoptosis analysis, nucleotide synthesis measurement, mouse xenograft model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical and cellular assays with in vivo validation; multiple orthogonal methods; preprint\",\n      \"pmids\": [\"bio_10.1101_2025.07.03.662851\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"Human ASNS catalyzes the ATP- and glutamine-dependent conversion of aspartate to asparagine (generating glutamate, AMP, and pyrophosphate); its transcription is directly activated by ATF4 binding to the NSRE-1 promoter element during amino acid deprivation, placing it downstream of the GCN2 kinase arm of the integrated stress response. ASNS protein stability is regulated by ubiquitin-proteasome degradation (controlled by mTORC1, VHL, and the GPS2/BTRC/ATF4 axis), while its mRNA stability is enhanced by METTL3-mediated m6A and METTL1-mediated m7G modifications. Disease-causing missense mutations reduce catalytic activity, and a cryo-EM structure of an uncompetitive small-molecule inhibitor (ASX-173) bound to the ASNS/AMP/Mg2+/pyrophosphate complex in the C-terminal synthetase domain has been determined, providing a structural basis for therapeutic targeting.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ASNS is the metabolic enzyme that catalyzes ATP-dependent de novo asparagine biosynthesis, with catalysis residing in a C-terminal synthetase domain where AMP, Mg2+, and pyrophosphate define the active-site architecture [#0]; disease-associated missense substitutions (R49Q, G289A, T337I) that diminish AMP-producing catalytic activity establish the enzyme's clinical importance [#1]. Its expression is governed primarily at the transcriptional level by the amino acid response: GCN2 kinase signaling drives recruitment of ATF4 to the ASNS promoter at the NSRE-1 element, where ATF4 binding is accompanied by activating histone marks (H3K4me3, H4 acetylation), to induce transcription during amino acid or asparagine deprivation [#2, #3, #4, #5]. ASNS abundance is further set by layered post-transcriptional and post-translational control: mRNA stability is enhanced by METTL3-mediated m6A modification [#7], while protein turnover is shaped by ubiquitin-proteasome degradation involving mTORC1 (which protects ASNS from degradation) [#6] and the VHL E3 ligase (which ubiquitinates ASNS) [#9]; the upstream ATF4 driver is itself stabilized by GPS2 blocking its BTRC-mediated degradation [#10]. Through this regulatory network ASNS modulates cellular asparagine supply with consequences for L-asparaginase sensitivity in leukemia [#11], CD8+ T cell effector differentiation [#13], and cortical neurogenesis [#14], and it is being pharmacologically targeted: the uncompetitive inhibitor ASX-173 binds the synthetase-domain ASNS/AMP/Mg2+/pyrophosphate complex and, combined with asparaginase, induces the integrated stress response and antitumor effects [#0, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established the transcriptional logic of ASNS induction by identifying ATF4 as the activator acting through the NSRE-1 promoter element under metabolic stress.\",\n      \"evidence\": \"Reporter assay of NSRE-1, ATF4 RNAi knockdown, and microarray in MELAS/NARP cybrid cells\",\n      \"pmids\": [\"17276738\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve the chromatin events accompanying ATF4 binding\", \"Upstream kinase signaling not defined in this study\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined the chromatin dynamics of ASNS activation, showing ATF4 recruitment coincides with specific histone modifications and reversible promoter remodeling during the amino acid response.\",\n      \"evidence\": \"ChIP for ATF4 and histone marks plus transcription run-on assays in HepG2 cells\",\n      \"pmids\": [\"22978410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional necessity of each histone mark for induction not dissected\", \"Did not establish the signaling kinase upstream of ATF4\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed GCN2 kinase upstream of ASNS in the amino acid response, linking sensing of asparagine depletion to ASNS induction and to asparaginase sensitivity in cancer.\",\n      \"evidence\": \"Pharmacological GCN2 inhibition with expression profiling, in vitro viability, and mouse xenografts in ALL/AML/pancreatic models\",\n      \"pmids\": [\"30061420\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relied on pharmacological inhibition rather than genetic ablation\", \"Direct GCN2-ATF4-ASNS molecular chain not reconstituted\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected epigenetic silencing of ASNS to drug response by showing allele-specific promoter methylation suppresses ASNS and predicts asparaginase sensitivity in leukemia.\",\n      \"evidence\": \"Bisulfite/allele-specific methylation mapping across three BCP-ALL cohorts and an ETV6-RUNX1 knockin mouse model\",\n      \"pmids\": [\"32573712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking 7q21 imprinting cluster to ASNS not fully defined\", \"Causal contribution of methylation versus correlation not isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Tested the prevailing assumption that ASNS level dictates asparaginase resistance, finding feedback suppression of biosynthesis by asparagine and that ASNS overexpression alone is insufficient for resistance in vivo.\",\n      \"evidence\": \"13C-glutamine isotope tracing and ASNS overexpression in a mouse B cell lymphoma model\",\n      \"pmids\": [\"35857457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Microenvironmental asparagine sources not fully accounted for\", \"Mechanism of biosynthetic feedback suppression not molecularly defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended ASNS function beyond housekeeping metabolism by identifying its expression dynamics as a regulator of CD8+ T cell effector versus memory differentiation.\",\n      \"evidence\": \"Single-cell RNA-seq, ASNS overexpression, and adoptive transfer in a mouse melanoma model\",\n      \"pmids\": [\"36384124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Metabolic versus signaling basis of the differentiation effect unresolved\", \"Whether catalytic activity is required not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Quantified the catalytic consequences of ASNS deficiency mutations, directly linking specific missense variants to graded loss of enzymatic activity.\",\n      \"evidence\": \"In vitro AMP-production assays of purified FLAG-tagged R49Q, G289A, T337I variants from HEK293T cells\",\n      \"pmids\": [\"37965492\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of activity loss for each variant not resolved\", \"Effects on protein stability or folding not separated from catalysis\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified dual upstream control of ASNS by TLK2, acting through ATF4 transcription and through mTORC1-mediated protection of ASNS protein from degradation.\",\n      \"evidence\": \"IP-MS, co-IP, and ubiquitination assays with pathway modulators\",\n      \"pmids\": [\"37542132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase opposing mTORC1 protection not identified here\", \"Direct versus indirect nature of mTORC1-ASNS interaction not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Confirmed direct ATF4 binding to the ASNS promoter in an independent cancer context, reinforcing the GCN2-ATF4-ASNS transcriptional axis.\",\n      \"evidence\": \"ChIP-qPCR with ATF4 gain- and loss-of-function in SW480 colon cancer cells\",\n      \"pmids\": [\"38844625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not add new mechanistic layers beyond confirming direct binding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Positioned ASNS downstream of DOT1L/EZH2 epigenetic regulation in cortical neurogenesis, where elevated ASNS promotes neuronal differentiation.\",\n      \"evidence\": \"DOT1L inhibition, scRNA-seq, lineage tracing, and ASNS overexpression rescue in neural progenitors\",\n      \"pmids\": [\"37382163\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional link from EZH2/PRC2 to ASNS not defined\", \"Whether the effect requires ASNS catalysis untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed m6A-based post-transcriptional control of ASNS, with METTL3 stabilizing ASNS mRNA to maintain protein levels and growth.\",\n      \"evidence\": \"MeRIP-qPCR, actinomycin D stability assay, luciferase reporter, and overexpression rescue\",\n      \"pmids\": [\"39132158\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A reader mediating stability not identified\", \"Specific m6A sites on ASNS mRNA not mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined the structural basis for therapeutic targeting of ASNS by solving an inhibitor-bound cryo-EM structure and showing uncompetitive inhibition that lowers asparagine and triggers the integrated stress response.\",\n      \"evidence\": \"Cryo-EM of ASX-173/ASNS/AMP/Mg2+/pyrophosphate plus in vitro kinetics and thermal shift assays (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.10.16.682859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Selectivity against related synthetases not detailed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified additional ubiquitin-proteasome and transcriptional repression nodes (VHL ubiquitination of ASNS; GPS2 stabilization of ATF4; HDAC5/RXRA repression) that set ASNS abundance and downstream signaling.\",\n      \"evidence\": \"Co-IP, ubiquitination/TMT proteomics, ChIP, and luciferase assays with in vivo validation across RCC, ALL, and cancer models\",\n      \"pmids\": [\"41943831\", \"40693356\", \"40781327\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Hierarchy among these regulators in a single cell type not established\", \"Reciprocal validation of some interactions limited to single labs\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Advanced ASNS as a druggable target with two distinct small-molecule inhibitors (ASX-173, PGG) showing antitumor and metabolic effects through enzymatic inhibition.\",\n      \"evidence\": \"Biochemical inhibition of purified ASNS, cellular and metabolic readouts, and mouse AML xenograft / MASLD models\",\n      \"pmids\": [\"bio_10.1101_2025.07.03.662851\", \"40409103\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Long-term resistance mechanisms not addressed\", \"ASX-173 evidence partly from preprint\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple parallel regulatory layers (GCN2/ATF4 transcription, m6A/m7G mRNA modification, mTORC1/VHL/GPS2-BTRC turnover, and epigenetic silencing) are integrated to set ASNS activity in a given tissue or tumor remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model relating transcriptional, post-transcriptional, and degradative control\", \"Tissue-specific dominance of each regulatory node unknown\", \"Relationship between ASNS catalytic output and its non-metabolic signaling roles undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 12]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [2, 3, 4]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ATF4\", \"mTORC1\", \"VHL\", \"USP13\", \"TLK2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":4,"faith_total":4,"faith_pct":100.0}}